General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Half-Life (Normalesrd) Hours
35/35
Plasma Protein Binding %
80-85
Volume Of Distribution L/Kg
10-40
Dose For Normal Renal Function
50 mg/m2 q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993; 45: 788-856. [PMID: 7686469] / Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet. 1994; 26: 428-38. [PMID: 8070217]
Toxicity Notes
Congeners have cardiotoxicity.